Recruiting PHASE2 INTERVENTIONAL 2-arm NCT03681275

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

A Clinical Trial of JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Interventions Placebo to match Tofacitinib Tofacitinib 10 MG [Xeljanz]

Updated 11 times since 2018 Last updated: Nov 21, 2024 Started: Sep 3, 2019 Primary completion: Nov 30, 2025 Completion: Nov 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03681275, this PHASE2 trial focuses on Diaphragm Injury and remains actively recruiting participants. Sponsored by National Heart, Lung, and Blood Institute (NHLBI), it has been updated 11 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Dec 2024 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Dec 2023 — May 2024 [monthly]

Recruiting PHASE2

▶ Show 6 earlier versions

Nov 2022 — Dec 2023 [monthly]

Recruiting PHASE2
Jun 2021 — Nov 2022 [monthly]

Recruiting PHASE2
Jan 2021 — Jun 2021 [monthly]

Recruiting PHASE2
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Phase: PHASE1 → PHASE2
Oct 2019 — Apr 2020 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Oct 2018 — Oct 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Heart, Lung, and Blood Institute (NHLBI)
Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States